Skip to main content

Sofwave Medical Appoints Medical Aesthetics Industry Expert James Bartholomeusz to the Role of Chief Innovation Officer

Written by Customer Service on . Posted in Public Companies.

SAN CLEMENTE, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) — Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced the appointment of James Bartholomeusz to the newly created position of Chief Innovation Officer. Mr. Bartholomeusz is a medical aesthetics expert and industry veteran with more than 20 years of experience. He will lead global product innovation, development, and go-to market strategies for new product launches.

“We are delighted to have James join Sofwave at this important stage of accelerated growth, product innovation and global expansion. His past leadership and track record in developing and launching new products includes driving the innovation and roll-out of groundbreaking body contouring technologies, leading-edge energy-based devices, and sophisticated skin treatment solutions, most notably the world’s first fractional RF device,” noted Louis Scafuri, CEO of Sofwave Medical. “We believe James’ relentless pursuit of innovation and excellence has positioned him at the forefront of the medical aesthetics industry. His past accolades serve as testament to his desire to redefine standards of care with a clear focus on long term patient experience. We look forward to the positive impact of James’ leadership, vision and expertise, as we strive to set new treatment innovation benchmarks in our industry.”

Commenting on his appointment, Mr. Bartholomeusz said, “I am honored to join Sofwave and have been impressed with the rapid adoption, acceptance, and growing reputation of the Company’s innovative SUPERB™ technology. Having helped develop and launch some of the industry’s most popular and effective conventional energy-based skin treatment solutions. I look forward to collaborating with the team to bring the very best, transformative non-invasive skin treatment solutions to the market and accelerate new product launches and market penetration for Sofwave products.”

Mr. Bartholomeusz joins Sofwave after his previous role as chief technology officer (CTO) at Lutronic, where he was responsible for developing and executing an ambitious 5-year product roadmap and growth strategy that included various industry defining products like DermaV before Lutronic was acquired by private equity in August of 2023. Prior to Lutronic Mr. Bartholomeusz served Syneron-Candela as Global Vice President of Product Development.

About Sofwave Medical
Sofwave Medical Ltd. has implemented an innovative approach to wrinkle reduction, lifting and cellulite using its proprietary breakthrough technology. SUPERB™, Synchronous Ultrasound Parallel Beam technology is FDA-cleared to improve facial lines and wrinkles, lifting the eyebrow and lifting lax submental tissue (beneath the chin) and neck tissue, the short-term improvement in the appearance of cellulite, improvement of skin laxity on upper arms and treatment of acne scars, providing physicians with smart yet simple, effective, and safe aesthetic solutions for their patients. Contact: Info@sofwave.com

Investor Contact:
Brian Ritchie
LifeSci Advisors LLC
(212) 915-2578
britchie@lifesciadvisors.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.